Publication | Closed Access

A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints

Pancreatic CancerMedicinePharmacologyPhase Ii StudyPharmacotherapyAdvanced Pancreatic Cancer5-Lipoxygenase InhibitorAnti-cancer AgentOncologyRadiation OncologyCancer Research